CIK 0001628171
- Large accelerated filer
Revolution Medicines, Inc.
Sign in to watch- Ticker
- RVMD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 472029180
- Phone
- +1 650-481-6801
- Business address
- 700 SAGINAW DR, REDWOOD CITY, CA, 94063
Securities
- RVMD Common Stock Nasdaq
- RVMDW Warrant Nasdaq
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,328,124
- in 21 filings, $85.3M under 10b5-1 plans
Net −$85,328,124. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-17 | Wei Lin Chief Medical Officer | Sale | −5,589 | $37.39 | $209K | 70,851 |
| 2024-06-03 | GOLDSMITH MARK A See Remarks | Option exercise 10b5-1 | +7,500 | $4.09 | $31K | 329,822 |
| 2024-06-03 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −900 | $39.09 | $35K | 328,922 |
| 2024-06-03 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −5,699 | $39.99 | $228K | 323,223 |
| 2024-06-03 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −901 | $40.93 | $37K | 322,322 |
| 2024-06-03 | GOLDSMITH MARK A See Remarks | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 316,229 | ||
| 2024-05-21 | Cislini Jeff General Counsel | Sale 10b5-1 | −700 | $38.67 | $27K | 53,674 |
| 2024-05-21 | Cislini Jeff General Counsel | Sale 10b5-1 | −800 | $39.51 | $32K | 52,874 |
| 2024-05-03 | Anders Jack Chief Financial Officer | Option exercise 10b5-1 | +10,000 | $2.68 | $27K | 111,959 |
| 2024-05-03 | Anders Jack Chief Financial Officer | Sale 10b5-1 | −10,000 | $40.03 | $400K | 101,959 |
| 2024-05-03 | Anders Jack Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 12,814 | ||
| 2024-04-10 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −7,500 | $35.48 | $266K | 452,879 |
| 2024-04-10 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −5,000 | $35.33 | $177K | 30,424 |
| 2024-04-10 | GOLDSMITH MARK A See Remarks | Sale 10b5-1 | −5,000 | $35.34 | $177K | 30,424 |
| 2024-04-10 | Patel Sushil Director | Option exercise 10b5-1 | +2,155 | $16.80 | $36K | 17,855 |
| 2024-04-10 | Patel Sushil Director | Sale 10b5-1 | −2,155 | $37.00 | $80K | 15,700 |
| 2024-04-10 | Patel Sushil Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,155 | 34,645 | ||
| 2024-03-27 | Cislini Jeff General Counsel | Sale 10b5-1 | −700 | $30.38 | $21K | 55,174 |
| 2024-03-27 | Cislini Jeff General Counsel | Sale 10b5-1 | −800 | $31.52 | $25K | 54,374 |
| 2024-03-18 | Cislini Jeff General Counsel | Sale 10b5-1 | −1,252 | $31.58 | $40K | 55,874 |
Page 26 of 29 · 569 trades